Fatemeh Farjadian

Dr. Fatemeh Farjadian

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Nanomedicine
Verified
Journal Article
Closed access
FFFatemeh Farjadian
Fatemeh Farjadian
AGAmir Ghasemi
Amir Ghasemi
OGOmid Gohari
Omid Gohari
ARAmir Roointan
Amir Roointan
MKMahdi Karimi
Mahdi Karimi
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.

1 September 2020 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
FFFatemeh Farjadian
Fatemeh Farjadian
SASomayeh Abbaspour
Somayeh Abbaspour
MSMohamad Amin Abdolahi Sadatlu
Mohamad Amin Abdolahi Sadatlu
SMSoroush Mirkiani
Soroush Mirkiani
AGAmir Ghasemi
Amir Ghasemi
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin

1 November 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MHMojtaba Hoseini-Ghahfarokhi
Mojtaba Hoseini-Ghahfarokhi
SMSoroush Mirkiani
Soroush Mirkiani
NMNaeimeh Mozaffari
Naeimeh Mozaffari
MSMohamad Amin Abdolahi Sadatlu
Mohamad Amin Abdolahi Sadatlu
AGAmir Ghasemi
Amir Ghasemi
MKMahdi Karimi
Mahdi Karimi
Graphene, a wonder material, has made far-reaching developments in many different fields such as materials science, electronics, condensed physics, quantum physics, energy systems, etc. Since its discovery in 2004, extensive studies have been done for understanding its physical and chemical properties. Owing to its unique characteristics, it has rapidly became a potential candidate for nano-bio researchers to explore its usage in biomedical applications. In the last decade, remarkable efforts have been devoted to investigating the biomedical utilization of graphene and graphene-based materials, especially in smart drug and gene delivery as well as cancer therapy. Inspired by a great number of successful graphene-based materials integrations into the biomedical area, here we summarize the most recent developments made about graphene applications in biomedicine. In this paper, we review the up-to-date advances of graphene-based materials in drug delivery applications, specifically targeted drug/ gene delivery, delivery of antitumor drugs, controlled and stimuli-responsive drug release, photodynamic therapy applications and optical imaging and theranostics, as well as investigating the future trends and succeeding challenges in this topic to provide an outlook for future researches.

1 March 2019 in Chemical Engineering Journal
Verified
Journal Article
Closed access
FFFatemeh Farjadian
Fatemeh Farjadian
ARAmir Roointan
Amir Roointan
SMSoliman Mohammadi-Samani
Soliman Mohammadi-Samani
MHMajid Hosseini
Majid Hosseini

1 July 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
EEElaheh Entezar-Almahdi
Elaheh Entezar-Almahdi
SMSoliman Mohammadi-Samani
Soliman Mohammadi-Samani
LTLobat Tayebi
Lobat Tayebi
FFFatemeh Farjadian
Fatemeh Farjadian
5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades. It is considered a first line antineoplastic agent for the treatment of colorectal cancer. Unfortunately, chemotherapy with 5-FU has several limitations, including its short half-life, high cytotoxicity and low bioavailability. In order to overcome the drawbacks of 5-FU and enhance its therapeutic efficiency, many scientific groups have focused on designing a new delivery system to successfully deliver 5-FU to tumor sites. We provide a comprehensive review on different strategies to design effective delivery systems, including nanoformulations, drug-conjugate formulations and other strategies for the delivery of 5-FU to colorectal cancer. Furthermore, co-delivery of 5-FU with other therapeutics is discussed. This review critically highlights the recent innovations in and literature on various types of carrier system for 5-FU.

1 July 2018 in Biotechnology Advances
Verified
Journal Article
Closed access
FFFatemeh Farjadian
Fatemeh Farjadian
MMMohsen Moghoofei
Mohsen Moghoofei
SMSoroush Mirkiani
Soroush Mirkiani
AGAmir Ghasemi
Amir Ghasemi
Navid RabieeNavid Rabiee
Navid Rabiee
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin